|Poll|October 3, 2022

POLL: Which September FDA Approval Were You Most Excited About?

Click here to answer this week's poll.

Which September FDA Approval Were You Most Excited About?

Dupilumab for prurigo nodularis
Deucravacitinib for psoriasis
DaxibotulinumtoxinA for glabellar lines
Spesolimab for generalized pustular psoriasis

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME